BCI
BCAX

Brinker Capital Investments’s Bicara Therapeutics BCAX Stock Holding History

Brinker Capital Investments’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
+9,255
New +$207K ﹤0.01% 1669
2026
Q1 		– Sell
-11,278
Closed -$190K – 2306
2025
Q4 		$190K Sell
11,278
-25
-0.2% -$427 ﹤0.01% 2035
2025
Q3 		$178K Buy
+11,303
New +$127K ﹤0.01% 1984

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brinker Capital Investments's BCAX Position: Q2 2026 in Review

Brinker Capital Investments opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 9,255 shares worth $275K. The stake represents ﹤0.01% of the portfolio and ranks #1669 among its holdings. This is a return to the name: Brinker Capital Investments previously reported a position in BCAX as recently as Q4 2025.

Brinker Capital Investments first reported a position in BCAX in Q3 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Brinker Capital Investments held 9,255 shares of Bicara Therapeutics worth $275K as of Q2 2026.
  • Bicara Therapeutics was a new Brinker Capital Investments position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1669 holding.
  • Brinker Capital Investments first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.